Sana Biotechnology, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $59.00K, a 60.14% decline year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $59.00K, a 94.76% decline year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $158.00K, a 91.85% decline year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $148.00K, a 93.73% decline year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $2.33M, a 75.50% decline from fiscal 2024.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $9.49M, a 369.95% increase from fiscal 2023.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $2.02M, a 10.34% decline from fiscal 2022.
- Sana Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $2.25M, a 28.86% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $59.00K 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $59.00K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $2.33M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $158.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $148.00K 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $1.13M 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $9.49M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $1.94M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $2.36M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $4.93M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.02M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $192.00K 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $691.00K 10-Q · filed 2024-11-08 | |
| 2023-03-31 | $331.00K 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $2.25M 10-K · filed 2025-03-17 | |
| 2022-09-30 | $897.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $571.00K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $652.00K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $3.17M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $1.60M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $333.00K 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $298.00K 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $149.00K 10-K · filed 2023-03-16 | |
| 2020-09-30 | $9.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $35.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $2.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $1.00K 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |